Ascensia Diabetes Care, a global diabetes care company, has announced a strategic partnership with Sava Technologies to advance wearable microsensor technology. The partnership will help Sava to introduce and commercialize its innovative wearable microsensor in the future. Ascensia is a subsidiary of PHC Holdings Corporation (TYO 6523) and Sava is a venture backed health technology start-up. The deal initially includes exclusive commercialization and distribution rights for Europe. Both companies have also entered into a concurrent financing agreement to support the development and market entry of the technology.
Strategic Partnership to Advance Glucose Monitoring
Under the agreement, Ascensia Diabetes Care will serve as the exclusive distribution partner for Sava’s microsensor technology, which remains under development. The wearable microsensor aims to continuously monitor relevant biomarkers and molecules beneath the skin. Glucose will be the first target of this innovative monitoring approach.
Unlike traditional continuous glucose monitors (CGMs) currently available on the market, Sava’s microsensor technology is designed to provide a minimally invasive glucose monitoring experience. Moreover, the technology aims to deliver additional health insights to users. This approach could offer new possibilities for people seeking convenient and continuous glucose monitoring solutions.
Today, continuous glucose monitoring is a key part of managing diabetes. Thus, advances in wearable health technologies could help to improve the daily monitoring experience for those living with diabetes. Ascensia and Sava will work together to combine established diabetes care knowledge with new microsensor technology.
Plans for clinical development and commercialization in Europe
Sava plans to commence a pivotal clinical trial for its continuous glucose monitoring technology this year. The company plans to seek CE approval and launch its wearable microsensor in the next 18 to 24 months following the study. The planned launch is for non-adjunctive use, which would enable users to make insulin dosing decisions without routine blood glucose monitoring confirmation.
Furthermore, the companies intend to make the continuous glucose monitoring technology available through retail channels. They also plan to work within established reimbursement structures. This distribution strategy aligns with Ascensia’s existing business model for blood glucose monitoring products.
Ascensia plans to start commercializing Sava’s microsensor technology in Europe, pending regulatory approval. The region is both companies first target for commercialization and both companies are based in Europe This will enable the partners to draw on Ascensia’s current commercial capabilities and experience in the diabetes care space.
However, the planned launch and distribution are subject to required regulatory approvals. The companies will have to meet the relevant requirements before commercializing the technology.
Ascensia Invests in Sava’s Microsensor Innovation
Along with the commercial agreement, Ascensia was the leader in Sava’s funding round (Series B). The diabetes management company also made a strategic equity investment into Sava, which evidences Ascensia’s desire to pursue innovations in welfare technologies that could be useful not only in glucose control.
Sava’s microsensors pave the way to measurement of a wider range of biomarkers and substances other than glucose, which opens up opportunities for new means of monitoring health conditions.
The partnership contributes to obtaining broader goals of PHC Holdings Corporation. PHC holdings Corporation and its subsidiaries operate under the name PHC Group, whose mission is to improve healthcare through technologies and solutions.
By combining investment with commercial collaboration, Ascensia and Sava are positioning their partnership around both immediate diabetes care needs and potential long-term healthcare applications. Nevertheless, future applications will depend on further development, validation and the relevant regulatory requirements.
Leadership Highlights the Potential of Microsensor Technology
Peter Bodlund, Chief Executive Officer of Ascensia, highlighted the potential impact of microsensors on everyday diabetes management.“Microsensors have the potential to transform the day-to-day monitoring experience for people with diabetes. By bringing together Sava’s innovative technology with Ascensia’s deep diabetes expertise, strong reputation and commercial capabilities, we have an exciting opportunity to address important unmet needs in diabetes care. This is an exciting step for Ascensia as we continue to broaden our portfolio and pursue our ambition to simplify and improve life for people with diabetes.”
His comments underline Ascensia’s focus on expanding its product portfolio through healthcare innovation. In addition, the collaboration reflects the company’s ambition to make diabetes management simpler for patients.
Rafaël Michali, Co-Founder and Co-CEO of Sava, also emphasized the value of working with an established diabetes care company.“Ascensia has spent decades earning the trust of people with diabetes and the clinicians who support them. Their strong global commercial organization, combined with our novel microsensor platform, gives us a route to a different monitoring experience at the scale this challenge demands. This partnership is the first step towards bringing that technology to the millions of people who need it.”
This is why Michali’s statement is so important: the connection between technological development and commercial reach. Sava provides its microsensor platform and Ascensia adds its experience serving people with diabetes and healthcare professionals.
Molding the Future of Diabetes Care
Ascensia Diabetes Care and Sava Technologies team up to develop new wearable glucose monitoring solutions. Both companies seek to address today’s challenges in diabetes management by combining microsensor innovation with strategic investment and distribution capabilities.
In the meantime, Sava is still seeking clinical evaluation and regulatory approval of its technology. Ascensia will support commercialization in Europe once required approvals are obtained.
In addition to glucose monitoring, the technology may also enable future advances in personalized healthcare. Ultimately, the partnership highlights the companies’ shared interest in advancing wearable health technology and discovering new avenues for ongoing monitoring.
Explore Health Tech Insiders for the latest medical innovations and reliable strategic insights driving the future of technology-driven healthcare transformation.
News Source: Businesswire.com
